-
1.
公开(公告)号:US20190240224A1
公开(公告)日:2019-08-08
申请号:US16266960
申请日:2019-02-04
申请人: Isofol Medical AB
IPC分类号: A61K31/519 , A61K9/00 , A61K45/06 , A61K39/395 , A61K31/4545 , A61K31/282 , A61P35/00 , A61K31/555 , A61K31/513 , A61K31/4745
CPC分类号: A61K31/519 , A61K9/0019 , A61K31/282 , A61K31/4545 , A61K31/4745 , A61K31/513 , A61K31/555 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/545 , A61P35/00 , C07K16/22 , C07K2317/24 , C07K2317/76 , A61K2300/00
摘要: The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.
-
2.
公开(公告)号:US20190231728A1
公开(公告)日:2019-08-01
申请号:US16377442
申请日:2019-04-08
发明人: Mark R. Kelley
IPC分类号: A61K31/201 , A61K33/24 , A61K31/7068 , A61K31/198 , A61K31/454 , A61K31/203 , A61K31/122 , A61K45/06 , A61K31/282 , A61K31/195 , A61K31/13 , A61K39/395
CPC分类号: A61K31/201 , A61K31/122 , A61K31/13 , A61K31/195 , A61K31/198 , A61K31/203 , A61K31/282 , A61K31/454 , A61K31/7068 , A61K33/24 , A61K39/3955 , A61K45/06 , A61K2300/00
摘要: Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component.
-
公开(公告)号:US20190216956A1
公开(公告)日:2019-07-18
申请号:US16255460
申请日:2019-01-23
IPC分类号: A61K51/04 , A61P35/00 , A61K51/12 , A61K38/14 , A61K51/02 , A61K31/704 , A61K33/243 , A61K31/337 , A61K31/282 , A61K31/407 , A61K31/7068
CPC分类号: A61K51/0497 , A61K31/282 , A61K31/337 , A61K31/407 , A61K31/704 , A61K31/7068 , A61K33/243 , A61K38/14 , A61K51/025 , A61K51/0453 , A61K51/1213 , A61P35/00
摘要: Provided herein are kits, compositions, and methods for treatment of a disease, disorder, or condition, such as a proliferative disease, disorder, or condition. One aspect provides a composition including a radioisotope and a substrate. Another aspect provides methods for treating a disease, disorder, or condition.
-
4.
公开(公告)号:US20190183843A9
公开(公告)日:2019-06-20
申请号:US15624200
申请日:2017-06-15
发明人: Jeffrey A. BACHA , Dennis M. BROWN , Anne STEINØ
IPC分类号: A61K31/336 , A61K31/4745 , A61K31/7048 , A61K31/502 , A61K33/24 , A61K31/282 , A61K31/495
CPC分类号: A61K31/336 , A61K31/282 , A61K31/4745 , A61K31/495 , A61K31/502 , A61K31/7048 , A61K33/24 , A61K45/06 , A61N5/10 , A61N2005/1098 , A61P35/00
摘要: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
-
公开(公告)号:US20180273618A1
公开(公告)日:2018-09-27
申请号:US15889532
申请日:2018-02-06
发明人: Christopher Lamond MURRIEL , Timothy Charles HOEY , Austin L. GURNEY , Julie Michelle RODA , Minu K. SRIVASTAVA , Inkyung PARK , Jakob DUPONT
IPC分类号: C07K16/28 , A61K31/519 , A61K39/395 , A61K31/282 , A61K39/00
CPC分类号: C07K16/28 , A61K31/282 , A61K31/519 , A61K39/39558 , A61K2039/507 , A61K2039/572 , C07K16/2803 , C07K16/2827 , C07K2317/24 , C07K2317/31 , C07K2317/76 , A61K39/395 , A61K2300/00
摘要: The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.
-
6.
公开(公告)号:US20180271921A1
公开(公告)日:2018-09-27
申请号:US15758689
申请日:2016-09-02
申请人: SillaJen, Inc.
发明人: Tae Ho HWANG , Nam Hee LEE , Euna CHO
IPC分类号: A61K35/768 , C12N9/18 , C07K14/565 , A61K38/46 , A61K38/21 , A61K45/06 , A61P35/00
CPC分类号: A61K35/768 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/7068 , A61K38/215 , A61K38/465 , A61K45/06 , A61K48/005 , A61P35/00 , C07K14/52 , C07K14/565 , C12N9/18 , C12N2710/24132 , C12N2710/24134 , C12N2710/24141 , C12N2710/24143 , C12Y301/01001 , A61K2300/00
摘要: The present disclosure pertains to a compositions and combinations for simultaneous, separate or sequential use which comprises (a) an oncolytic vaccinia virus that expresses a cytokine and a carboxylesterase enzyme, and, preferably, (b) a cancer co-drug, and to their uses for the treatment of cancer.
-
公开(公告)号:US20180221473A1
公开(公告)日:2018-08-09
申请号:US15705006
申请日:2017-09-14
申请人: Genentech, Inc.
发明人: Gwendolyn FYFE , Eric HOLMGREN , Robert D. MASS , William NOVOTNY
IPC分类号: A61K39/395 , A61K45/06 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , C07K16/30 , C07K16/22 , A61K9/00 , A61K31/7068 , A61K31/555 , A61K39/00
CPC分类号: A61K39/3955 , A61K9/0019 , A61K31/282 , A61K31/337 , A61K31/4545 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/522 , A61K31/525 , A61K31/555 , A61K31/573 , A61K31/7068 , A61K38/09 , A61K38/212 , A61K38/50 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/3046 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/76 , A61K2300/00
摘要: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
-
公开(公告)号:US20180207169A1
公开(公告)日:2018-07-26
申请号:US15744485
申请日:2016-07-15
发明人: Yong HUANG , Dominique P. BRIDON , Xuexiang ZHANG , Chien-Ming LI
IPC分类号: A61K31/5365 , A61K31/282 , A61K31/40 , A61P35/00 , A61P25/02 , A61K9/00 , A61K45/06
CPC分类号: A61K31/5365 , A61K9/0019 , A61K31/282 , A61K31/40 , A61K31/555 , A61K45/06 , A61P25/02 , A61P35/00 , A61K2300/00
摘要: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.
-
公开(公告)号:US20180193266A1
公开(公告)日:2018-07-12
申请号:US15917151
申请日:2018-03-09
发明人: Huang-Ge ZHANG
IPC分类号: A61K9/127 , A61K31/513 , A61K45/06 , A61K33/24 , A61K31/704 , A61K31/575 , A61K31/05 , A61K31/475 , A61K31/353 , A61K31/337 , A61K31/282 , A61K31/12
CPC分类号: A61K9/127 , A61K31/05 , A61K31/12 , A61K31/282 , A61K31/337 , A61K31/353 , A61K31/475 , A61K31/513 , A61K31/575 , A61K31/704 , A61K33/24 , A61K45/06 , A61K2300/00
摘要: An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions comprising the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer.
-
公开(公告)号:US10016480B2
公开(公告)日:2018-07-10
申请号:US15518216
申请日:2015-10-13
申请人: The United States of America, as represented by the Secretary, Department of Health and Human Services , Riptide Bioscience, Inc.
IPC分类号: A61K38/08 , A61K45/06 , C07K7/06 , C07K7/00 , A61K47/48 , A61K31/7068 , A61K31/337 , A61K31/513 , A61K31/519 , A61K31/4745 , A61K31/282
CPC分类号: A61K38/08 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/7068 , A61K36/10 , A61K38/04 , A61K38/10 , A61K38/16 , A61K45/06 , C07K5/08 , C07K5/10 , C07K7/06 , C07K7/08 , C07K14/00
摘要: Methods for treating a subject for pancreatic cancer via administration of small anti-inflammatory peptides are disclosed. The peptides may be administered in conjunction with another therapeutic agent, such as a chemotherapeutic agent, or therapeutic regimen. In some cases, the anti-inflammatory peptide that finds use in the subject methods has the amino acid sequence Lys-Phe-Arg-Lys-Ala-Phe-Lys-Arg-Phe-Phe (SEQ ID NO:1) or a multimer, derivative, or variant thereof.
-
-
-
-
-
-
-
-
-